Accelerating research by gaining insights into health and disease using structural biology tools.
The Protein Technologies Center (PTC) is a resource in the Department of Structural Biology. The PTC started its operations in 2019 and is unique as it integrates several techniques, from cloning to protein expression and purification, to biochemical/biophysical characterization and structure determination.
The expression of natural and recombinant proteins is an essential requisite for structural biology applications. More often than not, proteins are challenging to express outside their original host or in adequate quantity, even in the native host cell. The PTC solves difficult protein expression problems by employing semi-automated, multi-pronged approaches at each stage of the workflow, from construct design to cloning, expression, purification, and characterization of most protein targets, including membrane proteins, multi-protein complexes, and assemblies.
The PTC is staffed with expert scientists who have broad experience in gene cloning, protein production, purification, biophysical characterization, and structure determination. In particular, the staff has expertise in high-throughput technologies, handling membrane proteins and multi-protein complexes, cryo-EM (single-particle analysis), analytical ultracentrifugation, light scattering, surface plasmon resonance, microscale thermophoresis and isothermal titration calorimetry. The PTC is also committed to providing training and support for researchers at all levels who have particular needs with protein expression, purification, and biophysical characterization.
Access: Researchers from inside or outside the Department of Structural Biology should visit the PTC’s intranet pages for detailed information about the Center’s guidelines and services and to access the calendars for different instruments. Interested users are welcome to contact PTC staff members directly. Collaborative project proposals are assessed by the Director, in consultation with the Department Chair.
Ravi Kalathur received Ph.D. in biotechnology from India, collaborating with two labs in Germany (Profs. Rainer Rudolph and Wolfgang Schuhmann). Dr. Kalathur carried out postdoctoral work with Dr. Xinhua Ji at NCI/NIH, USA, on allosteric activation of E2-RING finger-mediated ubiquitylation. He then moved to Prof. Ian Wilson's lab at the Scripps, La Jolla, where he developed strategies to express challenging protein targets involved in the lipid-antigen presentation. Following his postdoctoral studies, Ravi joined the NYSBC, New York, as a scientist working on an NIH-funded structural genomics consortium on membrane proteins, under the leadership of Prof. Wayne Hendrickson. At the NYSBC, he developed high-throughput technologies to express eukaryotic membrane proteins. He was also key personnel in the NIH-funded P41 center grant (COMPPÅ). Ravi is an author of 21 publications with an h-index of 17.